Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Neutral Rating from Cantor Fitzgerald

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “neutral” rating reiterated by equities research analysts at Cantor Fitzgerald in a note issued to investors on Monday, Benzinga reports. They currently have a $1,015.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would suggest a potential downside of 12.15% from the company’s current price.

Other analysts have also recently issued research reports about the stock. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Argus upped their target price on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Piper Sandler increased their target price on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $1,250.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, September 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,109.70.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded up $1.98 during midday trading on Monday, hitting $1,155.33. 75,690 shares of the stock traded hands, compared to its average volume of 465,828. The firm has a 50-day moving average of $1,124.22 and a two-hundred day moving average of $1,026.46. The firm has a market capitalization of $127.30 billion, a P/E ratio of 34.13, a PEG ratio of 3.97 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. Regeneron Pharmaceuticals has a one year low of $769.19 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter last year, the firm earned $8.79 EPS. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the transaction, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at $41,311,496.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,026 shares of company stock worth $11,498,705. 7.48% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. West Paces Advisors Inc. raised its position in shares of Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares during the last quarter. Stephens Consulting LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $26,000. Sachetta LLC raised its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the period. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $28,000. Finally, Lynx Investment Advisory bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.